Protein clue could stop cancer "creep"

7 January 2008

Cancer Research UK scientists have unlocked the secrets of proteins involved in tumor cells creeping away from the original tumor and spreading around the body. Their findings were published in Molecular Cell on December 27, 2007.

The study involves a protein called Tes which appears to block cell growth and prevent tumours from forming. Scientists have now shown that it locks onto Mena - a protein involved in cell crawling that is found in excessive amounts in tumours. This is exciting, says CRUK, because Tes binds to Mena in an unexpected way compared with other proteins that interact with Mena. Crucially, when Tes binds to Mena, it stops cells from crawling as it blocks Mena from sticking to its usual binding partners.

The discovery offers the possibility of the development of drugs which could block the action of Mena by mimicking the action of Tes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight